Detalles de la búsqueda
1.
Effectiveness of Messenger RNA-1273 Vaccine Booster Against Coronavirus Disease 2019 in Immunocompetent Adults.
Clin Infect Dis
; 76(2): 252-262, 2023 01 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-36134518
2.
Distribution of SARS-CoV-2 Variants in a Large Integrated Health Care System - California, March-July 2021.
MMWR Morb Mortal Wkly Rep
; 70(40): 1415-1419, 2021 Oct 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-34618801
3.
Bacteria from bronchoalveolar lavage fluid from children with suspected chronic lower respiratory tract infection: results from a multi-center, cross-sectional study in Spain.
Eur J Pediatr
; 177(2): 181-192, 2018 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-29285648
4.
Effectiveness and durability of mRNA-1273 BA.4/BA.5 bivalent vaccine (mRNA-1273.222) against SARS-CoV-2 BA.4/BA.5 and XBB sublineages.
Hum Vaccin Immunother
; 20(1): 2335052, 2024 Dec 31.
Artículo
en Inglés
| MEDLINE | ID: mdl-38575149
5.
Authors' response to correspondence for EPI-STREP-064 publication.
Eur J Pediatr
; 177(9): 1411-1412, 2018 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-29948258
6.
Vaccine effectiveness of the mRNA-1273 3-dose primary series against COVID-19 in an immunocompromised population: A prospective observational cohort study.
Vaccine
; 41(24): 3636-3646, 2023 06 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37173268
7.
Effectiveness of a fourth dose of mRNA-1273 against COVID-19 among older adults in the United States: Interim results from an observational cohort study.
Vaccine
; 41(29): 4212-4219, 2023 06 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-37301708
8.
Effectiveness of mRNA-1273 vaccination against SARS-CoV-2 omicron subvariants BA.1, BA.2, BA.2.12.1, BA.4, and BA.5.
Nat Commun
; 14(1): 189, 2023 01 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-36635284
9.
mRNA-1273 bivalent (original and Omicron) COVID-19 vaccine effectiveness against COVID-19 outcomes in the United States.
Nat Commun
; 14(1): 5851, 2023 09 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-37730701
10.
The Population-Wide Risk-Benefit Profile of Extending the Primary COVID-19 Vaccine Course Compared with an mRNA Booster Dose Program.
Vaccines (Basel)
; 10(2)2022 Jan 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-35214599
11.
Durability of mRNA-1273 against COVID-19 in the time of Delta: Interim results from an observational cohort study.
PLoS One
; 17(4): e0267824, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-35482785
12.
Real-world effectiveness of the mRNA-1273 vaccine against COVID-19: Interim results from a prospective observational cohort study.
Lancet Reg Health Am
; 6: 100134, 2022 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-34849505
13.
Real-world comparative effectiveness of mRNA-1273 and BNT162b2 vaccines among immunocompromised adults identified in administrative claims data in the United States.
Vaccine
; 40(47): 6730-6739, 2022 11 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-36163093
14.
Effectiveness of mRNA-1273 against SARS-CoV-2 Omicron and Delta variants.
Nat Med
; 28(5): 1063-1071, 2022 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-35189624
15.
Vaccinating Adolescents and Children Significantly Reduces COVID-19 Morbidity and Mortality across All Ages: A Population-Based Modeling Study Using the UK as an Example.
Vaccines (Basel)
; 9(10)2021 Oct 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-34696288
16.
Effectiveness of mRNA-1273 against delta, mu, and other emerging variants of SARS-CoV-2: test negative case-control study.
BMJ
; 375: e068848, 2021 12 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-34911691
17.
The choice of analytical methodology can alter conclusions regarding herd effects of paediatric pneumococcal vaccination programmes.
Vaccine
; 36(46): 6933-6943, 2018 11 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-30316530
18.
Author Correction: Effectiveness of mRNA-1273 against SARS-CoV-2 Omicron and Delta variants.
Nat Med
; 28(5): 1095, 2022 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-35449419
Resultados
1 -
18
de 18
1
Próxima >
>>